Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be used to fight bird flu.

Today in History for Jan. 25: ...

In a report released today, Tyler Van Buren from TD Cowen maintained a Hold rating on Moderna (MRNA – Research Report), with a price target of ...

Goldman Sachs downgraded Moderna (MRNA) to Neutral from Buy with a price target of $51, down from $99. The recent product revenue guidance ...

RNA vaccines have been a long time coming, but were only approved after covid-19 emerged, marking the beginning of a new way of preventing – and treating – various conditions ...

The technology, used to make the initial COVID-19 vaccines, allows for a faster response to viruses that mutate quickly like influenza.

In July, the company received $176 million from HHS toward its vaccine efforts. Moderna plans to advance research on the mRNA ...

In the latest trading session, Moderna (MRNA) closed at $41.66, marking a +0.6% move from the previous day. The S&P 500 logs the best first week of a presidential term in four decades. Here are ...

Some dividend ETFs only invest in stocks within sectors for both risk and return reasons. Among these, Invesco KBW High ...

In this article, we are going to take a look at where Moderna Inc. (NASDAQ:MRNA) stands against other firms end 2024 stronger with impressive gains. A lackluster trading persisted throughout the ...

President Joe Biden's outgoing administration on Thursday announced $211 million in new funding to develop mRNA vaccines against emerging biothreats and said it was accelerating bird flu testing ...

(Reuters) -The U.S. government has awarded Moderna $590 million to advance the development of its bird flu vaccine, as the ...